{"gene":"ARID3A","run_date":"2026-06-09T22:02:44","timeline":{"discoveries":[{"year":2001,"finding":"Bright/ARID3A binds DNA through its ARID (A/T-rich interaction domain) and increases immunoglobulin heavy chain transcription 3-7 fold in antigen-activated B cells; Bruton's tyrosine kinase (Btk) is required for Bright binding activity, and Bright associates with nuclear matrix proteins sp100 and LYSp100B, suggesting roles in chromatin configuration and nuclear sublocalization.","method":"DNA binding assays, transcriptional reporter assays, protein-protein interaction studies","journal":"Immunologic research","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — functional transcriptional assays and binding studies reported across multiple early papers, single lab","pmids":["11594453"],"is_preprint":false},{"year":2006,"finding":"TFII-I directly interacts with Bright/ARID3A through amino acids in Bright's protein interaction domain; specific tyrosine residues of TFII-I (phosphorylated by Btk) are essential for Bright-induced immunoglobulin heavy chain reporter gene activity, establishing a three-component Bright–Btk–TFII-I complex at the immunoglobulin locus.","method":"Co-immunoprecipitation, reporter gene assay, dominant-negative TFII-I inhibition in B-cell lines, in vitro binding with deletion/point mutants","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal interaction mapping with mutants, functional reporter assay, inhibition of endogenous heavy-chain transcripts, multiple orthogonal methods in one study","pmids":["16738337"],"is_preprint":false},{"year":2007,"finding":"Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain (IgH) Eμ enhancer: Bright blocks nucleosome-mediated repression on chromatin-reconstituted templates, requires MAR (matrix attachment region) flanking sequences for maximal derepression, and increases DNase hypersensitivity of Eμ when added to B cell nuclear extracts.","method":"In vitro transcription on chromatin-reconstituted templates, DNase I hypersensitivity assay, competition with high-affinity P2 binding sites","journal":"Molecular cancer","confidence":"High","confidence_rationale":"Tier 1 / Moderate — reconstituted chromatin in vitro transcription system with mechanistic dissection, single lab but multiple orthogonal assays","pmids":["17386101"],"is_preprint":false},{"year":2003,"finding":"E2FBP1/DRIL1 (human ARID3A ortholog) is transcriptionally regulated by p53 via a p53-binding site in its second intron; its expression is induced by DNA damage (UV, doxorubicin) in a p53-dependent manner, and ectopic expression induces G1 growth arrest in p53-expressing cells but not p53-null cells.","method":"Luciferase reporter assay with p53-binding site, western blot after DNA damage, growth arrest assay in U2OS vs Saos-2 cells","journal":"Molecular cancer research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — functional reporter with defined binding site, isogenic p53+/- cell comparison, two orthogonal methods, single lab","pmids":["12692263"],"is_preprint":false},{"year":2008,"finding":"ARID3A/Dril1 physically interacts with Id1 (co-localization in vitro and in vivo); Id1 inhibits DNA binding by Dril1; Dril1 enhances activation of TGF-β1 target genes in fibroblasts, while Id1 suppresses the same targets, providing a mechanism whereby Id1 suppresses fibrosis through inhibition of Dril1's profibrotic transcriptional activity.","method":"Protein interaction screening (yeast two-hybrid), co-localization by imaging, DNA-binding competition assay, TGF-β1 target gene expression analysis in Id1-knockout fibroblasts","journal":"The American journal of pathology","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — interaction identified by pull-down/co-localization, functional gene expression readout, single lab","pmids":["18583319"],"is_preprint":false},{"year":2010,"finding":"Loss of Bright/ARID3A function in mouse models and human cells promotes developmental plasticity: Bright-deficient cells express pluripotency-associated gene products, expand indefinitely, and spontaneously differentiate into multiple lineages; direct knockdown of human Bright yields colonies capable of multi-lineage marker expression.","method":"Two mouse KO/inhibitor models, colony formation assay, lineage marker expression, siRNA knockdown of human ARID3A","journal":"Stem cells","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — loss-of-function with defined pluripotency phenotype, three independent lines of evidence, single lab","pmids":["20680960"],"is_preprint":false},{"year":2011,"finding":"ARID3A/DRIL1 cooperates with p53 to transcriptionally activate p21WAF1: ARID3A binds its cognate sites in the p21WAF1 promoter in vivo (ChIP) and in vitro, co-expression with p53 synergistically activates the p21WAF1 promoter, mutation of ARID3A binding sites reduces promoter activity, and ARID3A knockdown suppresses p21WAF1 induction (but not NOXA or PUMA) after DNA damage. ARID3A overexpression/knockdown reciprocally modulates p53 protein stability.","method":"ChIP, EMSA, luciferase reporter with mutant binding sites, siRNA knockdown, western blot","journal":"Biochemical and biophysical research communications","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — multiple orthogonal methods (ChIP, EMSA, reporter mutation, siRNA knockdown) establishing direct promoter binding and functional cooperation with p53","pmids":["22172947"],"is_preprint":false},{"year":2011,"finding":"Brightlike/ARID3C physically associates with Bright/ARID3A in solution and at common DNA binding sites in vitro; it co-activates Bright-dependent IgH transcription without significant transactivation capacity of its own; the unsumoylated form shows maximal co-activation; Brightlike undergoes nuclear-cytoplasmic shuttling and localizes in lipid rafts after BCR stimulation.","method":"Co-immunoprecipitation, in vitro DNA binding assay, IgH reporter gene assay, sumoylation analysis, subcellular fractionation/localization","journal":"Molecular immunology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — reciprocal interaction data, functional reporter assay, localization studies, single lab with multiple methods","pmids":["21955986"],"is_preprint":false},{"year":2012,"finding":"miR-125b directly targets and represses Bright/ARID3A in B-cell progenitors; repression of ARID3A blocks B-cell differentiation, confers survival advantage under IL-3 starvation, and promotes anti-apoptotic effects via caspase blockade independent of p53 and BAK1.","method":"miRNA target validation (luciferase reporter), loss-of-function with ARID3A knockdown/overexpression, apoptosis assays, patient sample expression correlation","journal":"Leukemia","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct target validation with reporter assay and rescue experiments, multiple cell lines, single lab","pmids":["22469780"],"is_preprint":false},{"year":2012,"finding":"ARID3A/Bright binds to the EBV C promoter (Cp) region and interacts with E2F1 and Oct-2; all three factors associate with EBNA1 in EBV-positive cell nuclei (co-IP and proximity ligation assay); ARID3A interaction was detected at Cp but not at the FR region of oriP, participating in long-distance promoter-enhancer interactions during EBV latency.","method":"DNA-affinity purification with mass spectrometry, co-immunoprecipitation, proximity ligation assay, ChIP","journal":"The Journal of general virology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple interaction detection methods (MS, Co-IP, PLA, ChIP) in a single study, single lab","pmids":["22302879"],"is_preprint":false},{"year":2014,"finding":"Bright/ARID3A acts as a barrier to somatic cell reprogramming by directly binding to promoter/enhancer regions of Oct4, Sox2, and Nanog and contributing to their repression in both MEFs and ESCs; Bright-deficient MEFs bypass senescence and spontaneously form pluripotent clones capable of teratoma formation and chimerism.","method":"ChIP at Oct4/Sox2/Nanog promoters, MEF reprogramming assay, teratoma/chimera formation, knockout MEF analysis","journal":"Stem cell reports","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP evidence for promoter binding plus functional reprogramming phenotype with in vivo validation, multiple orthogonal readouts","pmids":["24511468"],"is_preprint":false},{"year":2014,"finding":"Arid3a drives trophectoderm (TE) lineage commitment: nuclear entry of Arid3a activates TE-specific genes while directly repressing pluripotency genes via differential epigenetic regulation (acetylation/deacetylation at target loci); Arid3a null mice show severe placental defects causing early embryonic death; Arid3a acts upstream of and independently of Cdx2.","method":"ChIP for epigenetic marks, loss-of-function (Arid3a−/− mice), gain-of-function in ES cells, trophoblast stem cell assays","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP epigenetic evidence combined with KO phenotype, genetic epistasis with Cdx2, multiple orthogonal methods","pmids":["25319825"],"is_preprint":false},{"year":2015,"finding":"Arid3a is a key target of let-7 microRNA downstream of Lin28b in fetal B-1 lymphopoiesis: modulation of let-7 in fetal pro-B cells alters B-1 development; ectopic Arid3a expression is sufficient to induce B-1 development in adult pro-B cells, and Arid3a knockdown blocks B-1 development in fetal pro-B cells; intact BCR signaling is required for Lin28b/Arid3a-induced B1a generation.","method":"Retroviral transduction, let-7 modulation, shRNA knockdown of Arid3a, transplantation into immunodeficient recipients, BCR signaling blockade","journal":"The Journal of experimental medicine","confidence":"High","confidence_rationale":"Tier 2 / Strong — gain- and loss-of-function with defined pathway placement (Lin28b→let-7→Arid3a→B-1 fate), replicated across multiple experimental approaches","pmids":["25753579"],"is_preprint":false},{"year":2016,"finding":"ARID3A is required for mammalian placentation: it localizes to trophoblast giant cells and other trophoblast-derived subtypes; BMP4-mediated TS-like cell induction triggers cytoplasmic-to-nuclear translocation of ARID3A; ARID3A overexpression in BMP4-induced TS-like cells up-regulates TE markers and down-regulates pluripotency markers; null placentas show aberrant subtype-specific marker expression and altered cytokine/chemokine profiles.","method":"Immunohistochemistry/immunofluorescence for localization, conventional KO mouse model, ARID3A overexpression in human iPSC-derived TS-like cells, marker expression analysis","journal":"Developmental biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct subcellular localization tied to functional translocation event, KO phenotype with molecular marker analysis, single lab","pmids":["27965054"],"is_preprint":false},{"year":2016,"finding":"ARID3a+ human B lymphocytes constitute a novel effector B cell type that produces interferon alpha (IFNα); ARID3a expression is required for IFNα expression in B cells stimulated with TLR9 agonist CpG; IFNα secreted from ARID3a+ B cells stimulates increased IFNα production in plasmacytoid dendritic cells.","method":"Flow cytometry sorting of ARID3a+ B cells, CpG stimulation, ELISA/intracellular staining for IFNα, co-culture with pDCs","journal":"Journal of autoimmunity","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct functional assay linking ARID3a expression to IFNα production, cell-to-cell paracrine effect demonstrated, single lab","pmids":["27522115"],"is_preprint":false},{"year":2005,"finding":"Dril1/ARID3A is necessary for TGF-β (activin/Smad2 and BMP/Smad1) signaling in Xenopus embryos: morpholino knockdown of dril1 inhibits gastrulation, blocks induction of mesodermal and endodermal markers by activin/Smad2, and prevents ventral mesoderm induction by Smad1, while FGF-mediated mesoderm induction is unaffected, demonstrating pathway specificity; phenotype is rescued by dril1 mRNA co-injection.","method":"Morpholino knockdown, mRNA rescue, engrailed-repressor fusion (dominant negative), animal cap assay, marker gene expression (RT-PCR)","journal":"Developmental biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — morpholino KD with mRNA rescue, pathway-specific epistasis (TGF-β but not FGF), multiple orthogonal assays, replicated in two Xenopus species","pmids":["15680369"],"is_preprint":false},{"year":2019,"finding":"Arid3a binds to regeneration signal-response enhancers (RSREs) at the lhx1 locus (conserved from fish to human) and reduces H3K9me3 levels at these elements as a component of H3K9me3 demethylase complexes; Arid3a promotes cell cycle progression and nephric tubule outgrowth during regeneration; conditional knockdown of arid3a by photo-morpholino inhibits nephric tubule regeneration in Xenopus.","method":"Enhancer screen, ChIP for H3K9me3 and Arid3a binding, photo-morpholino conditional knockdown, cell cycle analysis","journal":"eLife","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP evidence for epigenetic mark reduction at bound elements, conditional KD with regeneration phenotype, multiple orthogonal methods","pmids":["30616715"],"is_preprint":false},{"year":2019,"finding":"miR-574-5p directly targets ARID3A mRNA in human cardiac fibroblasts (HCFs); decreased ARID3A levels promote fibroblast-to-myofibroblast differentiation in TGF-β-stimulated HCFs, as evidenced by altered fibrosis gene expression, proliferation, migration, and invasion assays.","method":"miRNA target validation (luciferase reporter), siRNA/mimic transfection, fibrosis marker expression, proliferation/migration/invasion assays","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct target validation with reporter assay, loss-of-function phenotype with multiple readouts, single lab","pmids":["31672272"],"is_preprint":false},{"year":2021,"finding":"ARID3A promotes colorectal cancer cell proliferation, migration, and invasion by transcriptionally activating Aurora kinase A (AURKA); ARID3A overexpression enhances, while knockdown suppresses, these malignant phenotypes in a manner dependent on AURKA.","method":"ARID3A overexpression/knockdown, cell proliferation/migration/invasion assays, AURKA expression analysis, rescue experiments","journal":"Carcinogenesis","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — gain- and loss-of-function with defined downstream target (AURKA), functional rescue, single lab","pmids":["33165575"],"is_preprint":false},{"year":2022,"finding":"ARID3A promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF-β-induced apoptosis and cell cycle arrest in a complex with SMAD2/3; posttranscriptional repression of ARID3A by miR-125b (encoded on chromosome 21) synergizes with Gata1s mutation to block megakaryocytic/erythroid differentiation and drive acute megakaryoblastic leukemia (AMKL); restoring ARID3A expression relieves differentiation block in AMKL patient-derived xenografts.","method":"Forward and reverse genetics, miR-125b target validation, SMAD2/3 co-immunoprecipitation, xenograft rescue experiments, flow cytometric differentiation assays","journal":"Blood","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal Co-IP for SMAD2/3 complex, xenograft rescue, genetic epistasis (miR-125b + Gata1s), multiple orthogonal methods across forward and reverse genetics","pmids":["34570885"],"is_preprint":false},{"year":2022,"finding":"ARID3A interacts with CEP131 and co-occupies the KDM3A promoter to transcriptionally activate KDM3A in liver cancer cells; KDM3A then demethylates H3K9me2 at downstream embryonic stem (ES) signature gene loci, upregulating their expression and promoting stemness and metastasis.","method":"Co-immunoprecipitation (ARID3A-CEP131), CUT&Tag chromatin profiling, RNA-seq, ChIP at KDM3A promoter, functional assays (viability, metastasis in vitro/in vivo)","journal":"Cell death & disease","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct chromatin occupancy (CUT&Tag), Co-IP interaction, RNA-seq for downstream targets, in vitro and in vivo functional validation, multiple orthogonal methods","pmids":["36008383"],"is_preprint":false},{"year":2023,"finding":"Arid3a negatively regulates Mertk transcription by directly binding to the Mertk promoter in macrophages; Arid3a-deficient macrophages show upregulated Mertk and enhanced efferocytosis of apoptotic cholangiocytes; myeloid-specific Arid3a knockout alleviates cholestatic liver injury in three murine models; in vitro Mertk inhibition reverses the protective phenotype of Arid3a deficiency.","method":"ChIP-seq for Arid3a at Mertk promoter, luciferase reporter assay, myeloid-specific KO mice, three cholestatic murine models, efferocytosis assay, pharmacological Mertk inhibition in vitro and in vivo","journal":"Journal of hepatology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — direct ChIP-seq evidence for promoter binding, luciferase reporter validation, myeloid KO with three disease models and pharmacological rescue, multiple orthogonal methods","pmids":["37659731"],"is_preprint":false},{"year":2024,"finding":"ARID3A transcriptionally represses PTEN in pancreatic cancer cells (CUT&Tag profiling shows ARID3A occupancy at PTEN promoter); decreased ARID3A relieves this repression, leading to PTEN upregulation, GPX4 depletion, increased lipid peroxidation, and ferroptosis activation, which suppresses tumor progression and gemcitabine resistance.","method":"CUT&Tag profiling, RNA-seq, ARID3A knockdown, in vitro and in vivo tumor assays, ferroptosis markers (lipid peroxidation, GPX4 levels)","journal":"Redox biology","confidence":"High","confidence_rationale":"Tier 1-2 / Strong — CUT&Tag chromatin profiling for direct target identification, RNA-seq for pathway analysis, in vitro and in vivo functional validation, multiple orthogonal methods","pmids":["38781729"],"is_preprint":false},{"year":1998,"finding":"The human DRIL1 gene (ARID3A) encodes an ARID family DNA-binding protein; its exon-intron structure was determined and it was physically mapped within 80 kb of marker D19S886 on chromosome 19p13.3.","method":"cDNA cloning, genomic mapping, Southern blot, physical linkage analysis","journal":"Genomics","confidence":"Medium","confidence_rationale":"Tier 3 / Moderate — direct molecular cloning and genomic characterization, single lab, foundational structural characterization","pmids":["9722953"],"is_preprint":false},{"year":2020,"finding":"ARID3A and its paralog ARID3B regulate nearly identical sets of genes in ovarian cancer cells (< 5% uniquely regulated), inducing stem cell and cancer-associated genes (Twist, MYCN, MMP2, GLI2, WNT5B); ARID3A and ARID3B also induce each other's expression, demonstrating cooperativity.","method":"Retroviral transduction of ARID3A-GFP and ARID3B-RFP, RNA-sequencing, gene set enrichment","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — RNA-seq with defined gain-of-function constructs, cross-induction validated, single lab","pmids":["32061921"],"is_preprint":false},{"year":2022,"finding":"ARID3A (porcine ortholog) binds to the promoter region of the pri-let-7a/let-7f/let-7d gene cluster and inhibits let-7 family expression in porcine alveolar macrophages; the NF-κB signaling pathway inhibits let-7 expression by affecting the nuclear import of ARID3A; this regulatory axis modulates PRRSV-2 replication.","method":"EMSA, ChIP, NF-κB pathway inhibition, nuclear import analysis","journal":"PLoS pathogens","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — EMSA and ChIP for direct promoter binding, nuclear import mechanistic analysis, but in porcine (non-mammalian orthologue context) cells with NF-κB pathway manipulation","pmids":["36215225"],"is_preprint":false}],"current_model":"ARID3A/Bright/DRIL1 is a nuclear ARID-domain transcription factor that binds AT-rich sequences in gene promoters and enhancers to activate (IgH locus, p21WAF1, KDM3A, AURKA, TE-specific genes) or repress (Oct4/Sox2/Nanog, PTEN, Mertk, let-7 cluster) target gene transcription, operates in multi-protein complexes with Btk/TFII-I, SMAD2/3, CEP131, and Id1, contributes to IgH enhancer chromatin accessibility by countering nucleosome repression, modulates H3K9me3 levels at regeneration enhancers, undergoes cytoplasmic-to-nuclear translocation in response to developmental cues, and regulates diverse processes including B-1 lymphopoiesis (downstream of Lin28b/let-7), trophectoderm fate and placentation, somatic cell reprogramming, macrophage efferocytosis, and hematopoietic lineage decisions."},"narrative":{"mechanistic_narrative":"ARID3A (Bright/DRIL1/E2FBP1) is a nuclear ARID-domain transcription factor that binds AT-rich promoter and enhancer sequences to direct context-specific gene activation or repression governing lymphocyte development, stem-cell/lineage fate, and epigenetic chromatin state [PMID:11594453, PMID:24511468, PMID:25319825]. It was first defined as an activator of immunoglobulin heavy chain (IgH) transcription, acting within a Bright–Btk–TFII-I complex at the IgH locus and countering nucleosome-mediated repression at the Eμ enhancer in a manner requiring matrix attachment region sequences to increase chromatin accessibility [PMID:16738337, PMID:17386101]. ARID3A operates as a barrier to developmental plasticity: it directly binds and represses the pluripotency genes Oct4, Sox2, and Nanog while activating lineage-specific programs, driving trophectoderm commitment and placentation through nuclear translocation triggered by developmental cues such as BMP4 [PMID:24511468, PMID:25319825, PMID:27965054]. In hematopoiesis it is a downstream effector of Lin28b/let-7 sufficient to instruct B-1 lymphopoiesis, cooperates with GATA1 and SMAD2/3 to promote megakaryocytic differentiation and TGF-β-induced apoptosis, and is repressed by miR-125b in acute megakaryoblastic leukemia [PMID:25753579, PMID:34570885]. ARID3A also functions through epigenetic complexes—reducing H3K9me3 at regeneration enhancers and partnering with CEP131 to activate the demethylase KDM3A—and exerts context-dependent control over cell cycle and tumor phenotypes by cooperating with p53 to activate p21WAF1 and by transcriptionally regulating AURKA, PTEN, and Mertk [PMID:30616715, PMID:36008383, PMID:22172947, PMID:33165575, PMID:38781729, PMID:37659731]. Its DNA binding is modulated by partners including Btk-dependent TFII-I phosphorylation and inhibitory Id1 interaction, integrating ARID3A into TGF-β/Smad signaling [PMID:16738337, PMID:18583319, PMID:15680369].","teleology":[{"year":1998,"claim":"Established the molecular identity of ARID3A as a chromosome 19p13.3 gene encoding an ARID-family DNA-binding protein, providing the structural foundation for all functional work.","evidence":"cDNA cloning and genomic/physical mapping","pmids":["9722953"],"confidence":"Medium","gaps":["No functional or binding-site data","ARID-domain DNA specificity not defined here"]},{"year":2001,"claim":"Showed that ARID3A binds AT-rich DNA via its ARID domain to activate IgH transcription, and that Btk is required for its DNA-binding activity, linking it to B-cell receptor signaling.","evidence":"DNA binding and reporter assays, protein-interaction studies in B cells","pmids":["11594453"],"confidence":"Medium","gaps":["Mechanism of Btk dependence not resolved","sp100/LYSp100B functional role unclear"]},{"year":2005,"claim":"Placed ARID3A genetically within TGF-β signaling, showing it is specifically required for activin/Smad2 and BMP/Smad1 (but not FGF) responses during embryonic germ-layer induction.","evidence":"Morpholino knockdown with mRNA rescue and pathway epistasis in Xenopus","pmids":["15680369"],"confidence":"High","gaps":["Direct Smad-ARID3A interaction not shown","Target genes in embryo not mapped"]},{"year":2006,"claim":"Resolved the IgH activation complex by mapping a three-component Bright–Btk–TFII-I assembly, with Btk-dependent TFII-I tyrosine phosphorylation required for ARID3A-driven transcription.","evidence":"Reciprocal Co-IP, interaction mapping with mutants, dominant-negative and reporter assays in B-cell lines","pmids":["16738337"],"confidence":"High","gaps":["Stoichiometry/architecture of the complex undefined","Generality beyond IgH locus untested"]},{"year":2007,"claim":"Defined the chromatin mechanism of ARID3A at the IgH Eμ enhancer, showing it relieves nucleosome-mediated repression and increases DNase hypersensitivity in a MAR-dependent manner.","evidence":"In vitro transcription on reconstituted chromatin and DNase I hypersensitivity assays","pmids":["17386101"],"confidence":"High","gaps":["No chromatin-remodeler partner identified","In vivo enhancer state not assayed"]},{"year":2003,"claim":"Connected ARID3A to the p53/DNA-damage axis, showing it is a p53 transcriptional target that induces p53-dependent G1 arrest.","evidence":"p53-binding-site reporter, DNA-damage induction, growth arrest in isogenic p53+/null cells","pmids":["12692263"],"confidence":"Medium","gaps":["Direct ARID3A target genes mediating arrest not identified here","Single-lab"]},{"year":2011,"claim":"Established a reciprocal ARID3A–p53 circuit by showing ARID3A directly binds the p21WAF1 promoter and cooperates with p53 to selectively activate p21 while modulating p53 protein stability.","evidence":"ChIP, EMSA, mutant reporters, siRNA knockdown, western blot","pmids":["22172947"],"confidence":"High","gaps":["Mechanism of p53 stabilization unresolved","Selectivity for p21 over NOXA/PUMA unexplained"]},{"year":2008,"claim":"Identified Id1 as a negative regulator that binds ARID3A and blocks its DNA binding, suppressing ARID3A's profibrotic TGF-β1 target activation.","evidence":"Yeast two-hybrid, co-localization, DNA-binding competition, target gene analysis in Id1-KO fibroblasts","pmids":["18583319"],"confidence":"Medium","gaps":["Direct profibrotic targets not enumerated","Single-lab interaction screen"]},{"year":2010,"claim":"Revealed ARID3A as a restraint on developmental plasticity, since its loss yields cells expressing pluripotency markers and capable of multi-lineage differentiation.","evidence":"Two mouse loss-of-function models, colony/lineage assays, human ARID3A knockdown","pmids":["20680960"],"confidence":"Medium","gaps":["Direct target genes not mapped in this study","Mechanism of plasticity not yet molecular"]},{"year":2014,"claim":"Provided the molecular basis for plasticity restraint, demonstrating ARID3A directly binds and represses Oct4/Sox2/Nanog promoters to act as a barrier to somatic reprogramming.","evidence":"ChIP at pluripotency promoters, MEF reprogramming, teratoma/chimera assays in knockout cells","pmids":["24511468"],"confidence":"High","gaps":["Repressive co-factor/complex not identified","Mechanism of senescence bypass unresolved"]},{"year":2014,"claim":"Showed ARID3A drives trophectoderm fate via nuclear entry that activates TE genes and epigenetically represses pluripotency genes, acting upstream of and independently of Cdx2.","evidence":"ChIP for histone marks, Arid3a-/- mice, ES/trophoblast stem cell gain-of-function, epistasis","pmids":["25319825"],"confidence":"High","gaps":["Enzymes mediating acetylation/deacetylation at targets not identified","Translocation trigger not defined here"]},{"year":2016,"claim":"Established ARID3A's requirement for placentation and identified BMP4 as a cue triggering its cytoplasmic-to-nuclear translocation to reprogram TE vs pluripotency markers.","evidence":"IHC/IF localization, conventional KO mice, overexpression in iPSC-derived TS-like cells","pmids":["27965054"],"confidence":"Medium","gaps":["Molecular machinery of nuclear import not defined","Direct TE target genes not ChIP-mapped"]},{"year":2015,"claim":"Positioned ARID3A as the effector node of the Lin28b/let-7 axis in B-1 lymphopoiesis, sufficient to impose fetal B-1 fate on adult progenitors and dependent on BCR signaling.","evidence":"Retroviral gain-of-function, let-7 modulation, shRNA knockdown, transplantation, BCR blockade","pmids":["25753579"],"confidence":"High","gaps":["Direct B-1 fate target genes not mapped","Mechanistic link to BCR signaling unresolved"]},{"year":2016,"claim":"Defined an IFNα-producing ARID3A+ effector B cell subset, showing ARID3A is required for TLR9-driven IFNα production with paracrine activation of plasmacytoid dendritic cells.","evidence":"Flow sorting, CpG stimulation, IFNα detection, co-culture with pDCs","pmids":["27522115"],"confidence":"Medium","gaps":["Direct ARID3A targets in IFNα program not identified","Relevance to autoimmunity correlative"]},{"year":2019,"claim":"Revealed an epigenetic-erasing role: ARID3A binds conserved regeneration enhancers at lhx1 and reduces H3K9me3 as part of demethylase complexes to drive cell-cycle progression and tubule regeneration.","evidence":"Enhancer screen, ChIP for Arid3a and H3K9me3, conditional photo-morpholino knockdown in Xenopus","pmids":["30616715"],"confidence":"High","gaps":["Identity of the demethylase enzyme not defined here","Recruitment mechanism to RSREs unknown"]},{"year":2012,"claim":"Defined miRNA control of ARID3A in B-cell progenitors, with miR-125b directly repressing it to block differentiation and confer p53-independent survival.","evidence":"miRNA reporter validation, knockdown/overexpression, apoptosis assays, patient correlation","pmids":["22469780"],"confidence":"Medium","gaps":["Anti-apoptotic effector downstream of ARID3A loss unidentified","Mechanism independent of p53/BAK1 unclear"]},{"year":2012,"claim":"Implicated ARID3A in viral chromatin architecture, showing it binds the EBV C promoter and forms a complex with E2F1, Oct-2, and EBNA1 mediating long-distance promoter-enhancer contacts during latency.","evidence":"DNA-affinity MS, Co-IP, proximity ligation assay, ChIP","pmids":["22302879"],"confidence":"Medium","gaps":["Functional consequence for EBV gene expression not quantified here","Direct vs bridged interactions not separated"]},{"year":2020,"claim":"Showed extensive functional redundancy and cross-regulation with paralog ARID3B, with both inducing stem/cancer gene programs and each other's expression in ovarian cancer.","evidence":"Retroviral gain-of-function and RNA-seq with gene set enrichment","pmids":["32061921"],"confidence":"Medium","gaps":["Direct vs indirect target distinction not made","Mechanism of mutual induction unknown"]},{"year":2021,"claim":"Linked ARID3A to oncogenic proliferation by showing it transcriptionally activates AURKA to drive colorectal cancer cell migration and invasion.","evidence":"Gain/loss-of-function, proliferation/migration/invasion assays, AURKA-dependent rescue","pmids":["33165575"],"confidence":"Medium","gaps":["Direct binding at AURKA promoter not demonstrated","Single-lab"]},{"year":2022,"claim":"Integrated ARID3A into megakaryocytic differentiation and leukemia, showing it cooperates with GATA1 and forms a SMAD2/3 complex mediating TGF-β apoptosis, with miR-125b repression synergizing with Gata1s to drive AMKL.","evidence":"Forward/reverse genetics, SMAD2/3 Co-IP, miR-125b validation, xenograft rescue, differentiation assays","pmids":["34570885"],"confidence":"High","gaps":["Direct ARID3A-GATA1 contact not shown","SMAD2/3 complex genomic targets not mapped"]},{"year":2022,"claim":"Defined an ARID3A-CEP131-KDM3A epigenetic cascade in which ARID3A activates the demethylase KDM3A to erase H3K9me2 at ES-signature loci, promoting stemness and metastasis in liver cancer.","evidence":"Co-IP, CUT&Tag, RNA-seq, ChIP at KDM3A promoter, in vitro/in vivo functional assays","pmids":["36008383"],"confidence":"High","gaps":["Role of CEP131 in chromatin recruitment unclear","Direct ARID3A binding at ES loci vs KDM3A-mediated indirect effect not fully separated"]},{"year":2022,"claim":"Defined a porcine-ortholog regulatory axis in which NF-κB controls ARID3A nuclear import to repress the let-7 cluster, modulating viral replication.","evidence":"EMSA, ChIP, NF-κB inhibition, nuclear import analysis in alveolar macrophages","pmids":["36215225"],"confidence":"Medium","gaps":["Mechanism by which NF-κB controls import undefined","Conservation in human cells not tested"]},{"year":2023,"claim":"Showed ARID3A directly represses Mertk in macrophages, with myeloid-specific loss enhancing efferocytosis and protecting against cholestatic liver injury.","evidence":"ChIP-seq, luciferase reporter, myeloid KO across three disease models, efferocytosis assay, pharmacological Mertk inhibition","pmids":["37659731"],"confidence":"High","gaps":["Co-repressor partners at Mertk promoter not identified","Upstream control of ARID3A in macrophages unclear"]},{"year":2024,"claim":"Established ARID3A as a ferroptosis suppressor, showing it occupies and represses the PTEN promoter, and its loss triggers PTEN-driven GPX4 depletion, lipid peroxidation, and ferroptosis in pancreatic cancer.","evidence":"CUT&Tag, RNA-seq, knockdown, in vitro/in vivo tumor assays, ferroptosis markers","pmids":["38781729"],"confidence":"High","gaps":["PTEN-to-GPX4 mechanistic link not fully resolved","Direct vs indirect repression details limited"]},{"year":null,"claim":"How ARID3A's intrinsic DNA-binding specificity is reprogrammed to act as activator vs repressor in different cell types, and what governs its regulated nuclear translocation, remain unresolved.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified model of activator/repressor switching","Nuclear import machinery and signal-dependent regulation undefined","Composition of repressive vs activating ARID3A complexes incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140110","term_label":"transcription regulator activity","supporting_discovery_ids":[0,6,10,11,18,21,22]},{"term_id":"GO:0003677","term_label":"DNA binding","supporting_discovery_ids":[0,6,10,21,25]},{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[4,7]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[0,11,13]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[13,25]}],"pathway":[{"term_id":"R-HSA-74160","term_label":"Gene expression (Transcription)","supporting_discovery_ids":[0,6,10,11,21,22]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[4,15,19]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[11,12,13]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[0,12,14]},{"term_id":"R-HSA-4839726","term_label":"Chromatin organization","supporting_discovery_ids":[2,16,20]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[18,19,22]}],"complexes":["Bright–Btk–TFII-I IgH complex","ARID3A–SMAD2/3 complex","ARID3A–CEP131 complex"],"partners":["BTK","GTF2I","ID1","SMAD2","SMAD3","CEP131","GATA1","ARID3B"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q99856","full_name":"AT-rich interactive domain-containing protein 3A","aliases":["B-cell regulator of IgH transcription","Bright","Dead ringer-like protein 1","E2F-binding protein 1"],"length_aa":593,"mass_kda":62.9,"function":"Transcription factor which may be involved in the control of cell cycle progression by the RB1/E2F1 pathway and in B-cell differentiation","subcellular_location":"Nucleus; Cytoplasm","url":"https://www.uniprot.org/uniprotkb/Q99856/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/ARID3A","classification":"Not Classified","n_dependent_lines":40,"n_total_lines":1208,"dependency_fraction":0.033112582781456956},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[],"url":"https://opencell.sf.czbiohub.org/search/ARID3A","total_profiled":1310},"omim":[{"mim_id":"620868","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3C; ARID3C","url":"https://www.omim.org/entry/620868"},{"mim_id":"612457","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3B; ARID3B","url":"https://www.omim.org/entry/612457"},{"mim_id":"611583","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 5A; ARID5A","url":"https://www.omim.org/entry/611583"},{"mim_id":"603265","title":"AT-RICH INTERACTION DOMAIN-CONTAINING PROTEIN 3A; ARID3A","url":"https://www.omim.org/entry/603265"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Additional"}],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"placenta","ntpm":22.0},{"tissue":"testis","ntpm":16.1}],"url":"https://www.proteinatlas.org/search/ARID3A"},"hgnc":{"alias_symbol":["BRIGHT"],"prev_symbol":["DRIL1"]},"alphafold":{"accession":"Q99856","domains":[{"cath_id":"1.10.150.60","chopping":"226-348","consensus_level":"high","plddt":95.0398,"start":226,"end":348}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99856","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q99856-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q99856-F1-predicted_aligned_error_v6.png","plddt_mean":60.59},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=ARID3A","jax_strain_url":"https://www.jax.org/strain/search?query=ARID3A"},"sequence":{"accession":"Q99856","fasta_url":"https://rest.uniprot.org/uniprotkb/Q99856.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q99856/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q99856"}},"corpus_meta":[{"pmid":"32060354","id":"PMC_32060354","title":"ROS in cancer therapy: the bright side of the moon.","date":"2020","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/32060354","citation_count":1515,"is_preprint":false},{"pmid":"23524392","id":"PMC_23524392","title":"A bright monomeric green fluorescent protein derived from Branchiostoma lanceolatum.","date":"2013","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/23524392","citation_count":1026,"is_preprint":false},{"pmid":"27869816","id":"PMC_27869816","title":"mScarlet: a bright monomeric red fluorescent protein for cellular imaging.","date":"2016","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/27869816","citation_count":871,"is_preprint":false},{"pmid":"27479746","id":"PMC_27479746","title":"The bright side of dark matter: lncRNAs in cancer.","date":"2016","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/27479746","citation_count":348,"is_preprint":false},{"pmid":"25101481","id":"PMC_25101481","title":"RNA mango aptamer-fluorophore: a bright, high-affinity complex for RNA labeling and tracking.","date":"2014","source":"ACS chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/25101481","citation_count":347,"is_preprint":false},{"pmid":"31371562","id":"PMC_31371562","title":"Bright and photostable chemigenetic indicators for extended in vivo voltage imaging.","date":"2019","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/31371562","citation_count":344,"is_preprint":false},{"pmid":"32979309","id":"PMC_32979309","title":"CAR T Cell Therapy for Solid Tumors: Bright Future or Dark Reality?","date":"2020","source":"Molecular therapy : the journal of the American Society of Gene Therapy","url":"https://pubmed.ncbi.nlm.nih.gov/32979309","citation_count":292,"is_preprint":false},{"pmid":"31548726","id":"PMC_31548726","title":"Visualizing RNA dynamics in live cells with bright and stable fluorescent RNAs.","date":"2019","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/31548726","citation_count":277,"is_preprint":false},{"pmid":"33189359","id":"PMC_33189359","title":"Extracellular vesicles: A bright star of nanomedicine.","date":"2020","source":"Biomaterials","url":"https://pubmed.ncbi.nlm.nih.gov/33189359","citation_count":275,"is_preprint":false},{"pmid":"27539380","id":"PMC_27539380","title":"Bright monomeric near-infrared fluorescent proteins as tags and biosensors for multiscale imaging.","date":"2016","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/27539380","citation_count":235,"is_preprint":false},{"pmid":"10449183","id":"PMC_10449183","title":"Reporter gene technology: the future looks bright.","date":"1999","source":"Biochemical pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/10449183","citation_count":223,"is_preprint":false},{"pmid":"35468954","id":"PMC_35468954","title":"A highly photostable and bright green fluorescent protein.","date":"2022","source":"Nature biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35468954","citation_count":219,"is_preprint":false},{"pmid":"20807678","id":"PMC_20807678","title":"Oncogene-induced senescence: the bright and dark side of the response.","date":"2010","source":"Current opinion in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/20807678","citation_count":181,"is_preprint":false},{"pmid":"32661427","id":"PMC_32661427","title":"Novel NanoLuc substrates enable bright two-population bioluminescence imaging in animals.","date":"2020","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/32661427","citation_count":145,"is_preprint":false},{"pmid":"30972335","id":"PMC_30972335","title":"NanoBRET: The Bright Future of Proximity-Based Assays.","date":"2019","source":"Frontiers in bioengineering and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30972335","citation_count":133,"is_preprint":false},{"pmid":"33208539","id":"PMC_33208539","title":"mGreenLantern: a bright monomeric fluorescent protein with rapid expression and cell filling properties for neuronal imaging.","date":"2020","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/33208539","citation_count":128,"is_preprint":false},{"pmid":"16084717","id":"PMC_16084717","title":"Anthocyans from fruits and vegetables--does bright colour signal cancer chemopreventive activity?","date":"2005","source":"European journal of cancer (Oxford, England : 1990)","url":"https://pubmed.ncbi.nlm.nih.gov/16084717","citation_count":124,"is_preprint":false},{"pmid":"34376677","id":"PMC_34376677","title":"The bright side of fibroblasts: molecular signature and regenerative cues in major organs.","date":"2021","source":"NPJ Regenerative medicine","url":"https://pubmed.ncbi.nlm.nih.gov/34376677","citation_count":122,"is_preprint":false},{"pmid":"29298292","id":"PMC_29298292","title":"Imaging organoids: a bright future ahead.","date":"2018","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/29298292","citation_count":112,"is_preprint":false},{"pmid":"24814217","id":"PMC_24814217","title":"Pheomelanin-induced oxidative stress: bright and dark chemistry bridging red hair phenotype and melanoma.","date":"2014","source":"Pigment cell & melanoma research","url":"https://pubmed.ncbi.nlm.nih.gov/24814217","citation_count":110,"is_preprint":false},{"pmid":"7513274","id":"PMC_7513274","title":"TOTO and YOYO: new very bright fluorochromes for DNA content analyses by flow cytometry.","date":"1994","source":"Cytometry","url":"https://pubmed.ncbi.nlm.nih.gov/7513274","citation_count":109,"is_preprint":false},{"pmid":"25753579","id":"PMC_25753579","title":"Lin28b promotes fetal B lymphopoiesis through the transcription factor Arid3a.","date":"2015","source":"The Journal of experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/25753579","citation_count":107,"is_preprint":false},{"pmid":"27589732","id":"PMC_27589732","title":"PMEL Amyloid Fibril Formation: The Bright Steps of Pigmentation.","date":"2016","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/27589732","citation_count":93,"is_preprint":false},{"pmid":"25493636","id":"PMC_25493636","title":"18F-Labeled Peptides: The Future Is Bright.","date":"2014","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/25493636","citation_count":91,"is_preprint":false},{"pmid":"24383451","id":"PMC_24383451","title":"TIGAR, TIGAR, burning bright.","date":"2014","source":"Cancer & metabolism","url":"https://pubmed.ncbi.nlm.nih.gov/24383451","citation_count":90,"is_preprint":false},{"pmid":"22991378","id":"PMC_22991378","title":"The bright and the dark sides of activin in wound healing and cancer.","date":"2012","source":"Journal of cell science","url":"https://pubmed.ncbi.nlm.nih.gov/22991378","citation_count":90,"is_preprint":false},{"pmid":"28733116","id":"PMC_28733116","title":"A Bright Future for Serial Femtosecond Crystallography with XFELs.","date":"2017","source":"Trends in biochemical sciences","url":"https://pubmed.ncbi.nlm.nih.gov/28733116","citation_count":86,"is_preprint":false},{"pmid":"17167795","id":"PMC_17167795","title":"Quantum dots and peptides: a bright future together.","date":"2007","source":"Biopolymers","url":"https://pubmed.ncbi.nlm.nih.gov/17167795","citation_count":80,"is_preprint":false},{"pmid":"30205559","id":"PMC_30205559","title":"MC1R: Front and Center in the Bright Side of Dark Eumelanin and DNA Repair.","date":"2018","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/30205559","citation_count":76,"is_preprint":false},{"pmid":"28779979","id":"PMC_28779979","title":"Cancer secretome and inflammation: The bright and the dark sides of NF-κB.","date":"2017","source":"Seminars in cell & developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/28779979","citation_count":75,"is_preprint":false},{"pmid":"30529586","id":"PMC_30529586","title":"A bright future: optogenetics to dissect the spatiotemporal control of cell behavior.","date":"2018","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/30529586","citation_count":73,"is_preprint":false},{"pmid":"38409224","id":"PMC_38409224","title":"Bright and stable monomeric green fluorescent protein derived from StayGold.","date":"2024","source":"Nature methods","url":"https://pubmed.ncbi.nlm.nih.gov/38409224","citation_count":67,"is_preprint":false},{"pmid":"35179300","id":"PMC_35179300","title":"Exosomal lncRNA HMMR-AS1 mediates macrophage polarization through miR-147a/ARID3A axis under hypoxia and affects the progression of hepatocellular carcinoma.","date":"2022","source":"Environmental toxicology","url":"https://pubmed.ncbi.nlm.nih.gov/35179300","citation_count":66,"is_preprint":false},{"pmid":"11682170","id":"PMC_11682170","title":"Green fluorescent protein--a bright idea for the study of bacterial protein localization.","date":"2001","source":"FEMS microbiology letters","url":"https://pubmed.ncbi.nlm.nih.gov/11682170","citation_count":60,"is_preprint":false},{"pmid":"32958033","id":"PMC_32958033","title":"The bright and the dark sides of L-carnitine supplementation: a systematic review.","date":"2020","source":"Journal of the International Society of Sports Nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/32958033","citation_count":58,"is_preprint":false},{"pmid":"16738337","id":"PMC_16738337","title":"Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I.","date":"2006","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/16738337","citation_count":52,"is_preprint":false},{"pmid":"34675420","id":"PMC_34675420","title":"Bright and stable luminescent probes for target engagement profiling in live cells.","date":"2021","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/34675420","citation_count":52,"is_preprint":false},{"pmid":"22469780","id":"PMC_22469780","title":"B-cell regulator of immunoglobulin heavy-chain transcription (Bright)/ARID3a is a direct target of the oncomir microRNA-125b in progenitor B-cells.","date":"2012","source":"Leukemia","url":"https://pubmed.ncbi.nlm.nih.gov/22469780","citation_count":50,"is_preprint":false},{"pmid":"26056741","id":"PMC_26056741","title":"Dark dyes-bright complexes: fluorogenic protein labeling.","date":"2015","source":"Current opinion in chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/26056741","citation_count":47,"is_preprint":false},{"pmid":"36455608","id":"PMC_36455608","title":"CAR T-cell therapies in China: rapid evolution and a bright future.","date":"2022","source":"The Lancet. Haematology","url":"https://pubmed.ncbi.nlm.nih.gov/36455608","citation_count":46,"is_preprint":false},{"pmid":"20680960","id":"PMC_20680960","title":"Loss of Bright/ARID3a function promotes developmental plasticity.","date":"2010","source":"Stem cells (Dayton, Ohio)","url":"https://pubmed.ncbi.nlm.nih.gov/20680960","citation_count":46,"is_preprint":false},{"pmid":"35550530","id":"PMC_35550530","title":"CD39 - A bright target for cancer immunotherapy.","date":"2022","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/35550530","citation_count":45,"is_preprint":false},{"pmid":"24511468","id":"PMC_24511468","title":"Bright/Arid3A acts as a barrier to somatic cell reprogramming through direct regulation of Oct4, Sox2, and Nanog.","date":"2014","source":"Stem cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/24511468","citation_count":43,"is_preprint":false},{"pmid":"25319825","id":"PMC_25319825","title":"Arid3a is essential to execution of the first cell fate decision via direct embryonic and extraembryonic transcriptional regulation.","date":"2014","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/25319825","citation_count":43,"is_preprint":false},{"pmid":"37490514","id":"PMC_37490514","title":"Bright-Field and Edge-Enhanced Imaging Using an Electrically Tunable Dual-Mode Metalens.","date":"2023","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/37490514","citation_count":42,"is_preprint":false},{"pmid":"28638470","id":"PMC_28638470","title":"Bright Polymer Dots Tracking Stem Cell Engraftment and Migration to Injured Mouse Liver.","date":"2017","source":"Theranostics","url":"https://pubmed.ncbi.nlm.nih.gov/28638470","citation_count":42,"is_preprint":false},{"pmid":"36658339","id":"PMC_36658339","title":"Avidity-based bright and photostable light-up aptamers for single-molecule mRNA imaging.","date":"2023","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/36658339","citation_count":41,"is_preprint":false},{"pmid":"32265667","id":"PMC_32265667","title":"A Bright and Colorful Future for G-Protein Coupled Receptor Sensors.","date":"2020","source":"Frontiers in cellular neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/32265667","citation_count":41,"is_preprint":false},{"pmid":"36865927","id":"PMC_36865927","title":"Protein dynamics: The future is bright and complicated!","date":"2023","source":"Structural dynamics (Melville, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/36865927","citation_count":40,"is_preprint":false},{"pmid":"18652084","id":"PMC_18652084","title":"Creatine and creatine kinase in health and disease--a bright future ahead?","date":"2007","source":"Sub-cellular biochemistry","url":"https://pubmed.ncbi.nlm.nih.gov/18652084","citation_count":40,"is_preprint":false},{"pmid":"38783134","id":"PMC_38783134","title":"Imaging the dynamics of messenger RNA with a bright and stable green fluorescent RNA.","date":"2024","source":"Nature chemical biology","url":"https://pubmed.ncbi.nlm.nih.gov/38783134","citation_count":38,"is_preprint":false},{"pmid":"30637228","id":"PMC_30637228","title":"Sulfonylurea and neuroprotection: The bright side of the moon.","date":"2018","source":"Journal of advanced pharmaceutical technology & research","url":"https://pubmed.ncbi.nlm.nih.gov/30637228","citation_count":38,"is_preprint":false},{"pmid":"36761757","id":"PMC_36761757","title":"Bright future or blind alley? CAR-T cell therapy for solid tumors.","date":"2023","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/36761757","citation_count":37,"is_preprint":false},{"pmid":"15270860","id":"PMC_15270860","title":"CD56(+dim) and CD56(+bright) cell activation and apoptosis in hepatitis C virus infection.","date":"2004","source":"Clinical and experimental immunology","url":"https://pubmed.ncbi.nlm.nih.gov/15270860","citation_count":36,"is_preprint":false},{"pmid":"33165575","id":"PMC_33165575","title":"ARID3A promotes the development of colorectal cancer by upregulating AURKA.","date":"2021","source":"Carcinogenesis","url":"https://pubmed.ncbi.nlm.nih.gov/33165575","citation_count":35,"is_preprint":false},{"pmid":"33777673","id":"PMC_33777673","title":"Can nanoparticles and nano‒protein interactions bring a bright future for insulin delivery?","date":"2020","source":"Acta pharmaceutica Sinica. B","url":"https://pubmed.ncbi.nlm.nih.gov/33777673","citation_count":35,"is_preprint":false},{"pmid":"17386101","id":"PMC_17386101","title":"Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain enhancer.","date":"2007","source":"Molecular cancer","url":"https://pubmed.ncbi.nlm.nih.gov/17386101","citation_count":35,"is_preprint":false},{"pmid":"20345907","id":"PMC_20345907","title":"A new bright green-emitting fluorescent protein--engineered monomeric and dimeric forms.","date":"2010","source":"The FEBS journal","url":"https://pubmed.ncbi.nlm.nih.gov/20345907","citation_count":35,"is_preprint":false},{"pmid":"37659731","id":"PMC_37659731","title":"A+T rich interaction domain protein 3a (Arid3a) impairs Mertk-mediated efferocytosis in cholestasis.","date":"2023","source":"Journal of hepatology","url":"https://pubmed.ncbi.nlm.nih.gov/37659731","citation_count":34,"is_preprint":false},{"pmid":"30833691","id":"PMC_30833691","title":"Bright sub-20-nm cathodoluminescent nanoprobes for electron microscopy.","date":"2019","source":"Nature nanotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/30833691","citation_count":34,"is_preprint":false},{"pmid":"34570885","id":"PMC_34570885","title":"The megakaryocytic transcription factor ARID3A suppresses leukemia pathogenesis.","date":"2022","source":"Blood","url":"https://pubmed.ncbi.nlm.nih.gov/34570885","citation_count":32,"is_preprint":false},{"pmid":"39325256","id":"PMC_39325256","title":"Personalized neoantigen cancer vaccines: current progression, challenges and a bright future.","date":"2024","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39325256","citation_count":30,"is_preprint":false},{"pmid":"36215225","id":"PMC_36215225","title":"miRNA let-7 family regulated by NEAT1 and ARID3A/NF-κB inhibits PRRSV-2 replication in vitro and in vivo.","date":"2022","source":"PLoS pathogens","url":"https://pubmed.ncbi.nlm.nih.gov/36215225","citation_count":30,"is_preprint":false},{"pmid":"27965054","id":"PMC_27965054","title":"ARID3A is required for mammalian placenta development.","date":"2016","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/27965054","citation_count":30,"is_preprint":false},{"pmid":"38350967","id":"PMC_38350967","title":"The role of CD56bright NK cells in neurodegenerative disorders.","date":"2024","source":"Journal of neuroinflammation","url":"https://pubmed.ncbi.nlm.nih.gov/38350967","citation_count":29,"is_preprint":false},{"pmid":"20396397","id":"PMC_20396397","title":"The bright and the dark sides of DNA repair in stem cells.","date":"2010","source":"Journal of biomedicine & biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/20396397","citation_count":29,"is_preprint":false},{"pmid":"24678314","id":"PMC_24678314","title":"The Bright Side of Hematopoiesis: Regulatory Roles of ARID3a/Bright in Human and Mouse Hematopoiesis.","date":"2014","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/24678314","citation_count":28,"is_preprint":false},{"pmid":"12692263","id":"PMC_12692263","title":"E2FBP1/DRIL1, an AT-rich interaction domain-family transcription factor, is regulated by p53.","date":"2003","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/12692263","citation_count":28,"is_preprint":false},{"pmid":"23597020","id":"PMC_23597020","title":"Bright ion channels and lipid bilayers.","date":"2013","source":"Accounts of chemical research","url":"https://pubmed.ncbi.nlm.nih.gov/23597020","citation_count":28,"is_preprint":false},{"pmid":"38781729","id":"PMC_38781729","title":"ARID3A enhances chemoresistance of pancreatic cancer via inhibiting PTEN-induced ferroptosis.","date":"2024","source":"Redox biology","url":"https://pubmed.ncbi.nlm.nih.gov/38781729","citation_count":27,"is_preprint":false},{"pmid":"32061921","id":"PMC_32061921","title":"ARID3A and ARID3B induce stem promoting pathways in ovarian cancer cells.","date":"2020","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/32061921","citation_count":27,"is_preprint":false},{"pmid":"27522115","id":"PMC_27522115","title":"Human effector B lymphocytes express ARID3a and secrete interferon alpha.","date":"2016","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/27522115","citation_count":26,"is_preprint":false},{"pmid":"30616715","id":"PMC_30616715","title":"Arid3a regulates nephric tubule regeneration via evolutionarily conserved regeneration signal-response enhancers.","date":"2019","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/30616715","citation_count":25,"is_preprint":false},{"pmid":"30430932","id":"PMC_30430932","title":"Building on Success: A Bright Future for Peptide Therapeutics.","date":"2018","source":"Protein and peptide letters","url":"https://pubmed.ncbi.nlm.nih.gov/30430932","citation_count":25,"is_preprint":false},{"pmid":"30297159","id":"PMC_30297159","title":"ARID3a gene profiles are strongly associated with human interferon alpha production.","date":"2018","source":"Journal of autoimmunity","url":"https://pubmed.ncbi.nlm.nih.gov/30297159","citation_count":24,"is_preprint":false},{"pmid":"9722953","id":"PMC_9722953","title":"The human dead ringer/bright homolog, DRIL1: cDNA cloning, gene structure, and mapping to D19S886, a marker on 19p13.3 that is strictly linked to the Peutz-Jeghers syndrome.","date":"1998","source":"Genomics","url":"https://pubmed.ncbi.nlm.nih.gov/9722953","citation_count":24,"is_preprint":false},{"pmid":"30900089","id":"PMC_30900089","title":"Vaccine vectors: the bright side of cytomegalovirus.","date":"2019","source":"Medical microbiology and immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30900089","citation_count":24,"is_preprint":false},{"pmid":"34928570","id":"PMC_34928570","title":"Amplified Fluorescence in Situ Hybridization by Small and Bright Dye-Loaded Polymeric Nanoparticles.","date":"2021","source":"ACS nano","url":"https://pubmed.ncbi.nlm.nih.gov/34928570","citation_count":24,"is_preprint":false},{"pmid":"30686614","id":"PMC_30686614","title":"Haem Biology in Metazoan Parasites - 'The Bright Side of Haem'.","date":"2019","source":"Trends in parasitology","url":"https://pubmed.ncbi.nlm.nih.gov/30686614","citation_count":24,"is_preprint":false},{"pmid":"18583319","id":"PMC_18583319","title":"Cross talk between Id1 and its interactive protein Dril1 mediate fibroblast responses to transforming growth factor-beta in pulmonary fibrosis.","date":"2008","source":"The American journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/18583319","citation_count":23,"is_preprint":false},{"pmid":"21955986","id":"PMC_21955986","title":"Characterization of a new ARID family transcription factor (Brightlike/ARID3C) that co-activates Bright/ARID3A-mediated immunoglobulin gene transcription.","date":"2011","source":"Molecular immunology","url":"https://pubmed.ncbi.nlm.nih.gov/21955986","citation_count":23,"is_preprint":false},{"pmid":"32558908","id":"PMC_32558908","title":"Getting DNA and RNA out of the dark with 2CNqA: a bright adenine analogue and interbase FRET donor.","date":"2020","source":"Nucleic acids research","url":"https://pubmed.ncbi.nlm.nih.gov/32558908","citation_count":23,"is_preprint":false},{"pmid":"26685208","id":"PMC_26685208","title":"The Transcription Factor ARID3a Is Important for In Vitro Differentiation of Human Hematopoietic Progenitors.","date":"2015","source":"Journal of immunology (Baltimore, Md. : 1950)","url":"https://pubmed.ncbi.nlm.nih.gov/26685208","citation_count":22,"is_preprint":false},{"pmid":"30930899","id":"PMC_30930899","title":"Crucial Role of Increased Arid3a at the Pre-B and Immature B Cell Stages for B1a Cell Generation.","date":"2019","source":"Frontiers in immunology","url":"https://pubmed.ncbi.nlm.nih.gov/30930899","citation_count":22,"is_preprint":false},{"pmid":"39061221","id":"PMC_39061221","title":"The Bright Side of Curcumin: A Narrative Review of Its Therapeutic Potential in Cancer Management.","date":"2024","source":"Cancers","url":"https://pubmed.ncbi.nlm.nih.gov/39061221","citation_count":22,"is_preprint":false},{"pmid":"38505631","id":"PMC_38505631","title":"Extracting quantitative biological information from bright-field cell images using deep learning.","date":"2021","source":"Biophysics reviews","url":"https://pubmed.ncbi.nlm.nih.gov/38505631","citation_count":22,"is_preprint":false},{"pmid":"36008383","id":"PMC_36008383","title":"Hepatic ARID3A facilitates liver cancer malignancy by cooperating with CEP131 to regulate an embryonic stem cell-like gene signature.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36008383","citation_count":21,"is_preprint":false},{"pmid":"31614870","id":"PMC_31614870","title":"The Bright and Dark Side of DNA Methylation: A Matter of Balance.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/31614870","citation_count":20,"is_preprint":false},{"pmid":"22302879","id":"PMC_22302879","title":"E2F1, ARID3A/Bright and Oct-2 factors bind to the Epstein-Barr virus C promoter, EBNA1 and oriP, participating in long-distance promoter-enhancer interactions.","date":"2012","source":"The Journal of general virology","url":"https://pubmed.ncbi.nlm.nih.gov/22302879","citation_count":20,"is_preprint":false},{"pmid":"28815751","id":"PMC_28815751","title":"Flow cytometry in Spermatology: A bright future ahead.","date":"2017","source":"Reproduction in domestic animals = Zuchthygiene","url":"https://pubmed.ncbi.nlm.nih.gov/28815751","citation_count":20,"is_preprint":false},{"pmid":"31672272","id":"PMC_31672272","title":"MiR-574-5p promotes the differentiation of human cardiac fibroblasts via regulating ARID3A.","date":"2019","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/31672272","citation_count":20,"is_preprint":false},{"pmid":"22172947","id":"PMC_22172947","title":"Cooperation between ARID3A and p53 in the transcriptional activation of p21WAF1 in response to DNA damage.","date":"2011","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/22172947","citation_count":19,"is_preprint":false},{"pmid":"36674884","id":"PMC_36674884","title":"Spotlight on P2X7 Receptor PET Imaging: A Bright Target or a Failing Star?","date":"2023","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/36674884","citation_count":19,"is_preprint":false},{"pmid":"31322869","id":"PMC_31322869","title":"Bright G-Quadruplex Nanostructures Functionalized with Porphyrin Lanterns.","date":"2019","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/31322869","citation_count":18,"is_preprint":false},{"pmid":"15680369","id":"PMC_15680369","title":"The ARID domain protein dril1 is necessary for TGF(beta) signaling in Xenopus embryos.","date":"2005","source":"Developmental biology","url":"https://pubmed.ncbi.nlm.nih.gov/15680369","citation_count":17,"is_preprint":false},{"pmid":"35133831","id":"PMC_35133831","title":"Engineering Bright and Mechanosensitive Alkaline-Earth Rare-Earth Upconverting Nanoparticles.","date":"2022","source":"The journal of physical chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/35133831","citation_count":17,"is_preprint":false},{"pmid":"36929909","id":"PMC_36929909","title":"Diversified Mammalian Visuasl Adaptations to Bright- or Dim-Light Environments.","date":"2023","source":"Molecular biology and evolution","url":"https://pubmed.ncbi.nlm.nih.gov/36929909","citation_count":16,"is_preprint":false},{"pmid":"38605649","id":"PMC_38605649","title":"2X-Rhodamine: A Bright and Fluorogenic Scaffold for Developing Near-Infrared Chemigenetic Indicators.","date":"2024","source":"Journal of the American Chemical Society","url":"https://pubmed.ncbi.nlm.nih.gov/38605649","citation_count":16,"is_preprint":false},{"pmid":"33494691","id":"PMC_33494691","title":"Novel Strategy in Breast Cancer Therapy: Revealing The Bright Side of Ginsenosides.","date":"2021","source":"Current molecular pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33494691","citation_count":16,"is_preprint":false},{"pmid":"11594453","id":"PMC_11594453","title":"The transcription factor, Bright, and immunoglobulin heavy chain expression.","date":"2001","source":"Immunologic research","url":"https://pubmed.ncbi.nlm.nih.gov/11594453","citation_count":15,"is_preprint":false}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":41214,"output_tokens":6871,"usd":0.113353,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15849,"output_tokens":6660,"usd":0.122872,"stage2_stop_reason":"end_turn"},"total_usd":0.236225,"stage1_batch_id":"msgbatch_0179Z2pxRYBsXi2xADneafRw","stage2_batch_id":"msgbatch_01LaY9ZaVdgjWArcZo9eqQE5","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2001,\n      \"finding\": \"Bright/ARID3A binds DNA through its ARID (A/T-rich interaction domain) and increases immunoglobulin heavy chain transcription 3-7 fold in antigen-activated B cells; Bruton's tyrosine kinase (Btk) is required for Bright binding activity, and Bright associates with nuclear matrix proteins sp100 and LYSp100B, suggesting roles in chromatin configuration and nuclear sublocalization.\",\n      \"method\": \"DNA binding assays, transcriptional reporter assays, protein-protein interaction studies\",\n      \"journal\": \"Immunologic research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — functional transcriptional assays and binding studies reported across multiple early papers, single lab\",\n      \"pmids\": [\"11594453\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"TFII-I directly interacts with Bright/ARID3A through amino acids in Bright's protein interaction domain; specific tyrosine residues of TFII-I (phosphorylated by Btk) are essential for Bright-induced immunoglobulin heavy chain reporter gene activity, establishing a three-component Bright–Btk–TFII-I complex at the immunoglobulin locus.\",\n      \"method\": \"Co-immunoprecipitation, reporter gene assay, dominant-negative TFII-I inhibition in B-cell lines, in vitro binding with deletion/point mutants\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal interaction mapping with mutants, functional reporter assay, inhibition of endogenous heavy-chain transcripts, multiple orthogonal methods in one study\",\n      \"pmids\": [\"16738337\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"Bright/ARID3A contributes to chromatin accessibility of the immunoglobulin heavy chain (IgH) Eμ enhancer: Bright blocks nucleosome-mediated repression on chromatin-reconstituted templates, requires MAR (matrix attachment region) flanking sequences for maximal derepression, and increases DNase hypersensitivity of Eμ when added to B cell nuclear extracts.\",\n      \"method\": \"In vitro transcription on chromatin-reconstituted templates, DNase I hypersensitivity assay, competition with high-affinity P2 binding sites\",\n      \"journal\": \"Molecular cancer\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — reconstituted chromatin in vitro transcription system with mechanistic dissection, single lab but multiple orthogonal assays\",\n      \"pmids\": [\"17386101\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2003,\n      \"finding\": \"E2FBP1/DRIL1 (human ARID3A ortholog) is transcriptionally regulated by p53 via a p53-binding site in its second intron; its expression is induced by DNA damage (UV, doxorubicin) in a p53-dependent manner, and ectopic expression induces G1 growth arrest in p53-expressing cells but not p53-null cells.\",\n      \"method\": \"Luciferase reporter assay with p53-binding site, western blot after DNA damage, growth arrest assay in U2OS vs Saos-2 cells\",\n      \"journal\": \"Molecular cancer research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — functional reporter with defined binding site, isogenic p53+/- cell comparison, two orthogonal methods, single lab\",\n      \"pmids\": [\"12692263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"ARID3A/Dril1 physically interacts with Id1 (co-localization in vitro and in vivo); Id1 inhibits DNA binding by Dril1; Dril1 enhances activation of TGF-β1 target genes in fibroblasts, while Id1 suppresses the same targets, providing a mechanism whereby Id1 suppresses fibrosis through inhibition of Dril1's profibrotic transcriptional activity.\",\n      \"method\": \"Protein interaction screening (yeast two-hybrid), co-localization by imaging, DNA-binding competition assay, TGF-β1 target gene expression analysis in Id1-knockout fibroblasts\",\n      \"journal\": \"The American journal of pathology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — interaction identified by pull-down/co-localization, functional gene expression readout, single lab\",\n      \"pmids\": [\"18583319\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"Loss of Bright/ARID3A function in mouse models and human cells promotes developmental plasticity: Bright-deficient cells express pluripotency-associated gene products, expand indefinitely, and spontaneously differentiate into multiple lineages; direct knockdown of human Bright yields colonies capable of multi-lineage marker expression.\",\n      \"method\": \"Two mouse KO/inhibitor models, colony formation assay, lineage marker expression, siRNA knockdown of human ARID3A\",\n      \"journal\": \"Stem cells\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — loss-of-function with defined pluripotency phenotype, three independent lines of evidence, single lab\",\n      \"pmids\": [\"20680960\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"ARID3A/DRIL1 cooperates with p53 to transcriptionally activate p21WAF1: ARID3A binds its cognate sites in the p21WAF1 promoter in vivo (ChIP) and in vitro, co-expression with p53 synergistically activates the p21WAF1 promoter, mutation of ARID3A binding sites reduces promoter activity, and ARID3A knockdown suppresses p21WAF1 induction (but not NOXA or PUMA) after DNA damage. ARID3A overexpression/knockdown reciprocally modulates p53 protein stability.\",\n      \"method\": \"ChIP, EMSA, luciferase reporter with mutant binding sites, siRNA knockdown, western blot\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — multiple orthogonal methods (ChIP, EMSA, reporter mutation, siRNA knockdown) establishing direct promoter binding and functional cooperation with p53\",\n      \"pmids\": [\"22172947\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Brightlike/ARID3C physically associates with Bright/ARID3A in solution and at common DNA binding sites in vitro; it co-activates Bright-dependent IgH transcription without significant transactivation capacity of its own; the unsumoylated form shows maximal co-activation; Brightlike undergoes nuclear-cytoplasmic shuttling and localizes in lipid rafts after BCR stimulation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro DNA binding assay, IgH reporter gene assay, sumoylation analysis, subcellular fractionation/localization\",\n      \"journal\": \"Molecular immunology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — reciprocal interaction data, functional reporter assay, localization studies, single lab with multiple methods\",\n      \"pmids\": [\"21955986\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"miR-125b directly targets and represses Bright/ARID3A in B-cell progenitors; repression of ARID3A blocks B-cell differentiation, confers survival advantage under IL-3 starvation, and promotes anti-apoptotic effects via caspase blockade independent of p53 and BAK1.\",\n      \"method\": \"miRNA target validation (luciferase reporter), loss-of-function with ARID3A knockdown/overexpression, apoptosis assays, patient sample expression correlation\",\n      \"journal\": \"Leukemia\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct target validation with reporter assay and rescue experiments, multiple cell lines, single lab\",\n      \"pmids\": [\"22469780\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2012,\n      \"finding\": \"ARID3A/Bright binds to the EBV C promoter (Cp) region and interacts with E2F1 and Oct-2; all three factors associate with EBNA1 in EBV-positive cell nuclei (co-IP and proximity ligation assay); ARID3A interaction was detected at Cp but not at the FR region of oriP, participating in long-distance promoter-enhancer interactions during EBV latency.\",\n      \"method\": \"DNA-affinity purification with mass spectrometry, co-immunoprecipitation, proximity ligation assay, ChIP\",\n      \"journal\": \"The Journal of general virology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple interaction detection methods (MS, Co-IP, PLA, ChIP) in a single study, single lab\",\n      \"pmids\": [\"22302879\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Bright/ARID3A acts as a barrier to somatic cell reprogramming by directly binding to promoter/enhancer regions of Oct4, Sox2, and Nanog and contributing to their repression in both MEFs and ESCs; Bright-deficient MEFs bypass senescence and spontaneously form pluripotent clones capable of teratoma formation and chimerism.\",\n      \"method\": \"ChIP at Oct4/Sox2/Nanog promoters, MEF reprogramming assay, teratoma/chimera formation, knockout MEF analysis\",\n      \"journal\": \"Stem cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP evidence for promoter binding plus functional reprogramming phenotype with in vivo validation, multiple orthogonal readouts\",\n      \"pmids\": [\"24511468\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Arid3a drives trophectoderm (TE) lineage commitment: nuclear entry of Arid3a activates TE-specific genes while directly repressing pluripotency genes via differential epigenetic regulation (acetylation/deacetylation at target loci); Arid3a null mice show severe placental defects causing early embryonic death; Arid3a acts upstream of and independently of Cdx2.\",\n      \"method\": \"ChIP for epigenetic marks, loss-of-function (Arid3a−/− mice), gain-of-function in ES cells, trophoblast stem cell assays\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP epigenetic evidence combined with KO phenotype, genetic epistasis with Cdx2, multiple orthogonal methods\",\n      \"pmids\": [\"25319825\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"Arid3a is a key target of let-7 microRNA downstream of Lin28b in fetal B-1 lymphopoiesis: modulation of let-7 in fetal pro-B cells alters B-1 development; ectopic Arid3a expression is sufficient to induce B-1 development in adult pro-B cells, and Arid3a knockdown blocks B-1 development in fetal pro-B cells; intact BCR signaling is required for Lin28b/Arid3a-induced B1a generation.\",\n      \"method\": \"Retroviral transduction, let-7 modulation, shRNA knockdown of Arid3a, transplantation into immunodeficient recipients, BCR signaling blockade\",\n      \"journal\": \"The Journal of experimental medicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — gain- and loss-of-function with defined pathway placement (Lin28b→let-7→Arid3a→B-1 fate), replicated across multiple experimental approaches\",\n      \"pmids\": [\"25753579\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARID3A is required for mammalian placentation: it localizes to trophoblast giant cells and other trophoblast-derived subtypes; BMP4-mediated TS-like cell induction triggers cytoplasmic-to-nuclear translocation of ARID3A; ARID3A overexpression in BMP4-induced TS-like cells up-regulates TE markers and down-regulates pluripotency markers; null placentas show aberrant subtype-specific marker expression and altered cytokine/chemokine profiles.\",\n      \"method\": \"Immunohistochemistry/immunofluorescence for localization, conventional KO mouse model, ARID3A overexpression in human iPSC-derived TS-like cells, marker expression analysis\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct subcellular localization tied to functional translocation event, KO phenotype with molecular marker analysis, single lab\",\n      \"pmids\": [\"27965054\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2016,\n      \"finding\": \"ARID3a+ human B lymphocytes constitute a novel effector B cell type that produces interferon alpha (IFNα); ARID3a expression is required for IFNα expression in B cells stimulated with TLR9 agonist CpG; IFNα secreted from ARID3a+ B cells stimulates increased IFNα production in plasmacytoid dendritic cells.\",\n      \"method\": \"Flow cytometry sorting of ARID3a+ B cells, CpG stimulation, ELISA/intracellular staining for IFNα, co-culture with pDCs\",\n      \"journal\": \"Journal of autoimmunity\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct functional assay linking ARID3a expression to IFNα production, cell-to-cell paracrine effect demonstrated, single lab\",\n      \"pmids\": [\"27522115\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2005,\n      \"finding\": \"Dril1/ARID3A is necessary for TGF-β (activin/Smad2 and BMP/Smad1) signaling in Xenopus embryos: morpholino knockdown of dril1 inhibits gastrulation, blocks induction of mesodermal and endodermal markers by activin/Smad2, and prevents ventral mesoderm induction by Smad1, while FGF-mediated mesoderm induction is unaffected, demonstrating pathway specificity; phenotype is rescued by dril1 mRNA co-injection.\",\n      \"method\": \"Morpholino knockdown, mRNA rescue, engrailed-repressor fusion (dominant negative), animal cap assay, marker gene expression (RT-PCR)\",\n      \"journal\": \"Developmental biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — morpholino KD with mRNA rescue, pathway-specific epistasis (TGF-β but not FGF), multiple orthogonal assays, replicated in two Xenopus species\",\n      \"pmids\": [\"15680369\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"Arid3a binds to regeneration signal-response enhancers (RSREs) at the lhx1 locus (conserved from fish to human) and reduces H3K9me3 levels at these elements as a component of H3K9me3 demethylase complexes; Arid3a promotes cell cycle progression and nephric tubule outgrowth during regeneration; conditional knockdown of arid3a by photo-morpholino inhibits nephric tubule regeneration in Xenopus.\",\n      \"method\": \"Enhancer screen, ChIP for H3K9me3 and Arid3a binding, photo-morpholino conditional knockdown, cell cycle analysis\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP evidence for epigenetic mark reduction at bound elements, conditional KD with regeneration phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"30616715\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"miR-574-5p directly targets ARID3A mRNA in human cardiac fibroblasts (HCFs); decreased ARID3A levels promote fibroblast-to-myofibroblast differentiation in TGF-β-stimulated HCFs, as evidenced by altered fibrosis gene expression, proliferation, migration, and invasion assays.\",\n      \"method\": \"miRNA target validation (luciferase reporter), siRNA/mimic transfection, fibrosis marker expression, proliferation/migration/invasion assays\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct target validation with reporter assay, loss-of-function phenotype with multiple readouts, single lab\",\n      \"pmids\": [\"31672272\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"ARID3A promotes colorectal cancer cell proliferation, migration, and invasion by transcriptionally activating Aurora kinase A (AURKA); ARID3A overexpression enhances, while knockdown suppresses, these malignant phenotypes in a manner dependent on AURKA.\",\n      \"method\": \"ARID3A overexpression/knockdown, cell proliferation/migration/invasion assays, AURKA expression analysis, rescue experiments\",\n      \"journal\": \"Carcinogenesis\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — gain- and loss-of-function with defined downstream target (AURKA), functional rescue, single lab\",\n      \"pmids\": [\"33165575\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A promotes megakaryocytic differentiation in concert with GATA1 and mediates TGF-β-induced apoptosis and cell cycle arrest in a complex with SMAD2/3; posttranscriptional repression of ARID3A by miR-125b (encoded on chromosome 21) synergizes with Gata1s mutation to block megakaryocytic/erythroid differentiation and drive acute megakaryoblastic leukemia (AMKL); restoring ARID3A expression relieves differentiation block in AMKL patient-derived xenografts.\",\n      \"method\": \"Forward and reverse genetics, miR-125b target validation, SMAD2/3 co-immunoprecipitation, xenograft rescue experiments, flow cytometric differentiation assays\",\n      \"journal\": \"Blood\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal Co-IP for SMAD2/3 complex, xenograft rescue, genetic epistasis (miR-125b + Gata1s), multiple orthogonal methods across forward and reverse genetics\",\n      \"pmids\": [\"34570885\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A interacts with CEP131 and co-occupies the KDM3A promoter to transcriptionally activate KDM3A in liver cancer cells; KDM3A then demethylates H3K9me2 at downstream embryonic stem (ES) signature gene loci, upregulating their expression and promoting stemness and metastasis.\",\n      \"method\": \"Co-immunoprecipitation (ARID3A-CEP131), CUT&Tag chromatin profiling, RNA-seq, ChIP at KDM3A promoter, functional assays (viability, metastasis in vitro/in vivo)\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct chromatin occupancy (CUT&Tag), Co-IP interaction, RNA-seq for downstream targets, in vitro and in vivo functional validation, multiple orthogonal methods\",\n      \"pmids\": [\"36008383\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"Arid3a negatively regulates Mertk transcription by directly binding to the Mertk promoter in macrophages; Arid3a-deficient macrophages show upregulated Mertk and enhanced efferocytosis of apoptotic cholangiocytes; myeloid-specific Arid3a knockout alleviates cholestatic liver injury in three murine models; in vitro Mertk inhibition reverses the protective phenotype of Arid3a deficiency.\",\n      \"method\": \"ChIP-seq for Arid3a at Mertk promoter, luciferase reporter assay, myeloid-specific KO mice, three cholestatic murine models, efferocytosis assay, pharmacological Mertk inhibition in vitro and in vivo\",\n      \"journal\": \"Journal of hepatology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — direct ChIP-seq evidence for promoter binding, luciferase reporter validation, myeloid KO with three disease models and pharmacological rescue, multiple orthogonal methods\",\n      \"pmids\": [\"37659731\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2024,\n      \"finding\": \"ARID3A transcriptionally represses PTEN in pancreatic cancer cells (CUT&Tag profiling shows ARID3A occupancy at PTEN promoter); decreased ARID3A relieves this repression, leading to PTEN upregulation, GPX4 depletion, increased lipid peroxidation, and ferroptosis activation, which suppresses tumor progression and gemcitabine resistance.\",\n      \"method\": \"CUT&Tag profiling, RNA-seq, ARID3A knockdown, in vitro and in vivo tumor assays, ferroptosis markers (lipid peroxidation, GPX4 levels)\",\n      \"journal\": \"Redox biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 / Strong — CUT&Tag chromatin profiling for direct target identification, RNA-seq for pathway analysis, in vitro and in vivo functional validation, multiple orthogonal methods\",\n      \"pmids\": [\"38781729\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1998,\n      \"finding\": \"The human DRIL1 gene (ARID3A) encodes an ARID family DNA-binding protein; its exon-intron structure was determined and it was physically mapped within 80 kb of marker D19S886 on chromosome 19p13.3.\",\n      \"method\": \"cDNA cloning, genomic mapping, Southern blot, physical linkage analysis\",\n      \"journal\": \"Genomics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 / Moderate — direct molecular cloning and genomic characterization, single lab, foundational structural characterization\",\n      \"pmids\": [\"9722953\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"ARID3A and its paralog ARID3B regulate nearly identical sets of genes in ovarian cancer cells (< 5% uniquely regulated), inducing stem cell and cancer-associated genes (Twist, MYCN, MMP2, GLI2, WNT5B); ARID3A and ARID3B also induce each other's expression, demonstrating cooperativity.\",\n      \"method\": \"Retroviral transduction of ARID3A-GFP and ARID3B-RFP, RNA-sequencing, gene set enrichment\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — RNA-seq with defined gain-of-function constructs, cross-induction validated, single lab\",\n      \"pmids\": [\"32061921\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"ARID3A (porcine ortholog) binds to the promoter region of the pri-let-7a/let-7f/let-7d gene cluster and inhibits let-7 family expression in porcine alveolar macrophages; the NF-κB signaling pathway inhibits let-7 expression by affecting the nuclear import of ARID3A; this regulatory axis modulates PRRSV-2 replication.\",\n      \"method\": \"EMSA, ChIP, NF-κB pathway inhibition, nuclear import analysis\",\n      \"journal\": \"PLoS pathogens\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — EMSA and ChIP for direct promoter binding, nuclear import mechanistic analysis, but in porcine (non-mammalian orthologue context) cells with NF-κB pathway manipulation\",\n      \"pmids\": [\"36215225\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"ARID3A/Bright/DRIL1 is a nuclear ARID-domain transcription factor that binds AT-rich sequences in gene promoters and enhancers to activate (IgH locus, p21WAF1, KDM3A, AURKA, TE-specific genes) or repress (Oct4/Sox2/Nanog, PTEN, Mertk, let-7 cluster) target gene transcription, operates in multi-protein complexes with Btk/TFII-I, SMAD2/3, CEP131, and Id1, contributes to IgH enhancer chromatin accessibility by countering nucleosome repression, modulates H3K9me3 levels at regeneration enhancers, undergoes cytoplasmic-to-nuclear translocation in response to developmental cues, and regulates diverse processes including B-1 lymphopoiesis (downstream of Lin28b/let-7), trophectoderm fate and placentation, somatic cell reprogramming, macrophage efferocytosis, and hematopoietic lineage decisions.\"\n}\n```","stage2_raw":"{\n  \"mechanistic_narrative\": \"ARID3A (Bright/DRIL1/E2FBP1) is a nuclear ARID-domain transcription factor that binds AT-rich promoter and enhancer sequences to direct context-specific gene activation or repression governing lymphocyte development, stem-cell/lineage fate, and epigenetic chromatin state [#0, #10, #11]. It was first defined as an activator of immunoglobulin heavy chain (IgH) transcription, acting within a Bright–Btk–TFII-I complex at the IgH locus and countering nucleosome-mediated repression at the E\\u03bc enhancer in a manner requiring matrix attachment region sequences to increase chromatin accessibility [#1, #2]. ARID3A operates as a barrier to developmental plasticity: it directly binds and represses the pluripotency genes Oct4, Sox2, and Nanog while activating lineage-specific programs, driving trophectoderm commitment and placentation through nuclear translocation triggered by developmental cues such as BMP4 [#10, #11, #13]. In hematopoiesis it is a downstream effector of Lin28b/let-7 sufficient to instruct B-1 lymphopoiesis, cooperates with GATA1 and SMAD2/3 to promote megakaryocytic differentiation and TGF-\\u03b2-induced apoptosis, and is repressed by miR-125b in acute megakaryoblastic leukemia [#12, #19]. ARID3A also functions through epigenetic complexes\\u2014reducing H3K9me3 at regeneration enhancers and partnering with CEP131 to activate the demethylase KDM3A\\u2014and exerts context-dependent control over cell cycle and tumor phenotypes by cooperating with p53 to activate p21WAF1 and by transcriptionally regulating AURKA, PTEN, and Mertk [#16, #20, #6, #18, #22, #21]. Its DNA binding is modulated by partners including Btk-dependent TFII-I phosphorylation and inhibitory Id1 interaction, integrating ARID3A into TGF-\\u03b2/Smad signaling [#1, #4, #15].\",\n  \"teleology\": [\n    {\n      \"year\": 1998,\n      \"claim\": \"Established the molecular identity of ARID3A as a chromosome 19p13.3 gene encoding an ARID-family DNA-binding protein, providing the structural foundation for all functional work.\",\n      \"evidence\": \"cDNA cloning and genomic/physical mapping\",\n      \"pmids\": [\"9722953\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No functional or binding-site data\", \"ARID-domain DNA specificity not defined here\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"Showed that ARID3A binds AT-rich DNA via its ARID domain to activate IgH transcription, and that Btk is required for its DNA-binding activity, linking it to B-cell receptor signaling.\",\n      \"evidence\": \"DNA binding and reporter assays, protein-interaction studies in B cells\",\n      \"pmids\": [\"11594453\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism of Btk dependence not resolved\", \"sp100/LYSp100B functional role unclear\"]\n    },\n    {\n      \"year\": 2005,\n      \"claim\": \"Placed ARID3A genetically within TGF-\\u03b2 signaling, showing it is specifically required for activin/Smad2 and BMP/Smad1 (but not FGF) responses during embryonic germ-layer induction.\",\n      \"evidence\": \"Morpholino knockdown with mRNA rescue and pathway epistasis in Xenopus\",\n      \"pmids\": [\"15680369\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct Smad-ARID3A interaction not shown\", \"Target genes in embryo not mapped\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Resolved the IgH activation complex by mapping a three-component Bright\\u2013Btk\\u2013TFII-I assembly, with Btk-dependent TFII-I tyrosine phosphorylation required for ARID3A-driven transcription.\",\n      \"evidence\": \"Reciprocal Co-IP, interaction mapping with mutants, dominant-negative and reporter assays in B-cell lines\",\n      \"pmids\": [\"16738337\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Stoichiometry/architecture of the complex undefined\", \"Generality beyond IgH locus untested\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the chromatin mechanism of ARID3A at the IgH E\\u03bc enhancer, showing it relieves nucleosome-mediated repression and increases DNase hypersensitivity in a MAR-dependent manner.\",\n      \"evidence\": \"In vitro transcription on reconstituted chromatin and DNase I hypersensitivity assays\",\n      \"pmids\": [\"17386101\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No chromatin-remodeler partner identified\", \"In vivo enhancer state not assayed\"]\n    },\n    {\n      \"year\": 2003,\n      \"claim\": \"Connected ARID3A to the p53/DNA-damage axis, showing it is a p53 transcriptional target that induces p53-dependent G1 arrest.\",\n      \"evidence\": \"p53-binding-site reporter, DNA-damage induction, growth arrest in isogenic p53+/null cells\",\n      \"pmids\": [\"12692263\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ARID3A target genes mediating arrest not identified here\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established a reciprocal ARID3A\\u2013p53 circuit by showing ARID3A directly binds the p21WAF1 promoter and cooperates with p53 to selectively activate p21 while modulating p53 protein stability.\",\n      \"evidence\": \"ChIP, EMSA, mutant reporters, siRNA knockdown, western blot\",\n      \"pmids\": [\"22172947\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of p53 stabilization unresolved\", \"Selectivity for p21 over NOXA/PUMA unexplained\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified Id1 as a negative regulator that binds ARID3A and blocks its DNA binding, suppressing ARID3A's profibrotic TGF-\\u03b21 target activation.\",\n      \"evidence\": \"Yeast two-hybrid, co-localization, DNA-binding competition, target gene analysis in Id1-KO fibroblasts\",\n      \"pmids\": [\"18583319\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct profibrotic targets not enumerated\", \"Single-lab interaction screen\"]\n    },\n    {\n      \"year\": 2010,\n      \"claim\": \"Revealed ARID3A as a restraint on developmental plasticity, since its loss yields cells expressing pluripotency markers and capable of multi-lineage differentiation.\",\n      \"evidence\": \"Two mouse loss-of-function models, colony/lineage assays, human ARID3A knockdown\",\n      \"pmids\": [\"20680960\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct target genes not mapped in this study\", \"Mechanism of plasticity not yet molecular\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Provided the molecular basis for plasticity restraint, demonstrating ARID3A directly binds and represses Oct4/Sox2/Nanog promoters to act as a barrier to somatic reprogramming.\",\n      \"evidence\": \"ChIP at pluripotency promoters, MEF reprogramming, teratoma/chimera assays in knockout cells\",\n      \"pmids\": [\"24511468\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Repressive co-factor/complex not identified\", \"Mechanism of senescence bypass unresolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Showed ARID3A drives trophectoderm fate via nuclear entry that activates TE genes and epigenetically represses pluripotency genes, acting upstream of and independently of Cdx2.\",\n      \"evidence\": \"ChIP for histone marks, Arid3a-/- mice, ES/trophoblast stem cell gain-of-function, epistasis\",\n      \"pmids\": [\"25319825\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Enzymes mediating acetylation/deacetylation at targets not identified\", \"Translocation trigger not defined here\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Established ARID3A's requirement for placentation and identified BMP4 as a cue triggering its cytoplasmic-to-nuclear translocation to reprogram TE vs pluripotency markers.\",\n      \"evidence\": \"IHC/IF localization, conventional KO mice, overexpression in iPSC-derived TS-like cells\",\n      \"pmids\": [\"27965054\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular machinery of nuclear import not defined\", \"Direct TE target genes not ChIP-mapped\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Positioned ARID3A as the effector node of the Lin28b/let-7 axis in B-1 lymphopoiesis, sufficient to impose fetal B-1 fate on adult progenitors and dependent on BCR signaling.\",\n      \"evidence\": \"Retroviral gain-of-function, let-7 modulation, shRNA knockdown, transplantation, BCR blockade\",\n      \"pmids\": [\"25753579\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct B-1 fate target genes not mapped\", \"Mechanistic link to BCR signaling unresolved\"]\n    },\n    {\n      \"year\": 2016,\n      \"claim\": \"Defined an IFN\\u03b1-producing ARID3A+ effector B cell subset, showing ARID3A is required for TLR9-driven IFN\\u03b1 production with paracrine activation of plasmacytoid dendritic cells.\",\n      \"evidence\": \"Flow sorting, CpG stimulation, IFN\\u03b1 detection, co-culture with pDCs\",\n      \"pmids\": [\"27522115\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct ARID3A targets in IFN\\u03b1 program not identified\", \"Relevance to autoimmunity correlative\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Revealed an epigenetic-erasing role: ARID3A binds conserved regeneration enhancers at lhx1 and reduces H3K9me3 as part of demethylase complexes to drive cell-cycle progression and tubule regeneration.\",\n      \"evidence\": \"Enhancer screen, ChIP for Arid3a and H3K9me3, conditional photo-morpholino knockdown in Xenopus\",\n      \"pmids\": [\"30616715\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Identity of the demethylase enzyme not defined here\", \"Recruitment mechanism to RSREs unknown\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Defined miRNA control of ARID3A in B-cell progenitors, with miR-125b directly repressing it to block differentiation and confer p53-independent survival.\",\n      \"evidence\": \"miRNA reporter validation, knockdown/overexpression, apoptosis assays, patient correlation\",\n      \"pmids\": [\"22469780\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Anti-apoptotic effector downstream of ARID3A loss unidentified\", \"Mechanism independent of p53/BAK1 unclear\"]\n    },\n    {\n      \"year\": 2012,\n      \"claim\": \"Implicated ARID3A in viral chromatin architecture, showing it binds the EBV C promoter and forms a complex with E2F1, Oct-2, and EBNA1 mediating long-distance promoter-enhancer contacts during latency.\",\n      \"evidence\": \"DNA-affinity MS, Co-IP, proximity ligation assay, ChIP\",\n      \"pmids\": [\"22302879\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Functional consequence for EBV gene expression not quantified here\", \"Direct vs bridged interactions not separated\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Showed extensive functional redundancy and cross-regulation with paralog ARID3B, with both inducing stem/cancer gene programs and each other's expression in ovarian cancer.\",\n      \"evidence\": \"Retroviral gain-of-function and RNA-seq with gene set enrichment\",\n      \"pmids\": [\"32061921\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect target distinction not made\", \"Mechanism of mutual induction unknown\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Linked ARID3A to oncogenic proliferation by showing it transcriptionally activates AURKA to drive colorectal cancer cell migration and invasion.\",\n      \"evidence\": \"Gain/loss-of-function, proliferation/migration/invasion assays, AURKA-dependent rescue\",\n      \"pmids\": [\"33165575\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding at AURKA promoter not demonstrated\", \"Single-lab\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Integrated ARID3A into megakaryocytic differentiation and leukemia, showing it cooperates with GATA1 and forms a SMAD2/3 complex mediating TGF-\\u03b2 apoptosis, with miR-125b repression synergizing with Gata1s to drive AMKL.\",\n      \"evidence\": \"Forward/reverse genetics, SMAD2/3 Co-IP, miR-125b validation, xenograft rescue, differentiation assays\",\n      \"pmids\": [\"34570885\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct ARID3A-GATA1 contact not shown\", \"SMAD2/3 complex genomic targets not mapped\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined an ARID3A-CEP131-KDM3A epigenetic cascade in which ARID3A activates the demethylase KDM3A to erase H3K9me2 at ES-signature loci, promoting stemness and metastasis in liver cancer.\",\n      \"evidence\": \"Co-IP, CUT&Tag, RNA-seq, ChIP at KDM3A promoter, in vitro/in vivo functional assays\",\n      \"pmids\": [\"36008383\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Role of CEP131 in chromatin recruitment unclear\", \"Direct ARID3A binding at ES loci vs KDM3A-mediated indirect effect not fully separated\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Defined a porcine-ortholog regulatory axis in which NF-\\u03baB controls ARID3A nuclear import to repress the let-7 cluster, modulating viral replication.\",\n      \"evidence\": \"EMSA, ChIP, NF-\\u03baB inhibition, nuclear import analysis in alveolar macrophages\",\n      \"pmids\": [\"36215225\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism by which NF-\\u03baB controls import undefined\", \"Conservation in human cells not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed ARID3A directly represses Mertk in macrophages, with myeloid-specific loss enhancing efferocytosis and protecting against cholestatic liver injury.\",\n      \"evidence\": \"ChIP-seq, luciferase reporter, myeloid KO across three disease models, efferocytosis assay, pharmacological Mertk inhibition\",\n      \"pmids\": [\"37659731\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Co-repressor partners at Mertk promoter not identified\", \"Upstream control of ARID3A in macrophages unclear\"]\n    },\n    {\n      \"year\": 2024,\n      \"claim\": \"Established ARID3A as a ferroptosis suppressor, showing it occupies and represses the PTEN promoter, and its loss triggers PTEN-driven GPX4 depletion, lipid peroxidation, and ferroptosis in pancreatic cancer.\",\n      \"evidence\": \"CUT&Tag, RNA-seq, knockdown, in vitro/in vivo tumor assays, ferroptosis markers\",\n      \"pmids\": [\"38781729\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"PTEN-to-GPX4 mechanistic link not fully resolved\", \"Direct vs indirect repression details limited\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"How ARID3A's intrinsic DNA-binding specificity is reprogrammed to act as activator vs repressor in different cell types, and what governs its regulated nuclear translocation, remain unresolved.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified model of activator/repressor switching\", \"Nuclear import machinery and signal-dependent regulation undefined\", \"Composition of repressive vs activating ARID3A complexes incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140110\", \"supporting_discovery_ids\": [0, 6, 10, 11, 18, 21, 22]},\n      {\"term_id\": \"GO:0003677\", \"supporting_discovery_ids\": [0, 6, 10, 21, 25]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [4, 7]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [0, 11, 13]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [13, 25]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-74160\", \"supporting_discovery_ids\": [0, 6, 10, 11, 21, 22]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [4, 15, 19]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [11, 12, 13]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [0, 12, 14]},\n      {\"term_id\": \"R-HSA-4839726\", \"supporting_discovery_ids\": [2, 16, 20]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [18, 19, 22]}\n    ],\n    \"complexes\": [\n      \"Bright\\u2013Btk\\u2013TFII-I IgH complex\",\n      \"ARID3A\\u2013SMAD2/3 complex\",\n      \"ARID3A\\u2013CEP131 complex\"\n    ],\n    \"partners\": [\n      \"BTK\",\n      \"GTF2I\",\n      \"ID1\",\n      \"SMAD2\",\n      \"SMAD3\",\n      \"CEP131\",\n      \"GATA1\",\n      \"ARID3B\"\n    ],\n    \"other_free_text\": []\n  }\n}","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":6,"faith_total":6,"faith_pct":100.0}}